Israeli scientists have discovered a new cancer treatment method

Posted by MOMOLI on October 11, 2008 in Cancer

Israeli scientists recently found that the two will be manufactured in accordance with the requirements for the right combination of antibodies, which form a network, more conducive to destroy cancer cells in communications networks, the end, the body of rehabilitation.

After 30 years on cancer research, is the so-called “HER” the receptor has been identified by, as they sat on the same antenna outside the cell wall, suggesting a certain type of cancer. Weitzman Institute Arden professor leading the research team in the study had found that under certain conditions, HER2 receptor can enhance the development of cells to receive signals. To that end, researchers developed a method of producing specific antibodies, these antibodies can be independent not only bound by these special receptors of cancer, and can be connected with the closure of the network signal.

In test-tube experiments and tests in mice, the researchers exposed the cancer cells of two different antibodies before, with the HER2 receptor antibody to connect. In the interaction, the researchers found that the receptor framework of the distinctly different attachment points, two different antibodies have shown that a cooperative rather than competitive, resulting in a significantly between the receptor, a Flexible molecular scaffold. Chain and traction system to seize a nearly receptors each other, until the result of a set of internal collapse. These cells were swallowed up by receptor, thus stop the signal. Accordingly, the cells stop development, while at this time if the use of chemotherapy and immunotherapy, will lead to cell death.

Arden believes that their research opens up antibodies - the receptor for collaboration advantage. Research results show that, if the use of different antibodies to the right collaboration, receptor degradation will be accelerated, that is, in inhibiting HER2 signal, the effect of collaboration than just the use of a more than three times the antibody.

Arden said: “The understanding of the HER receptor degradation is how to carry out, will be able to improve the treatment, but will also provide us with a way to enable patients to overcome inherent or external resistance to cancer treatment.”